Gene
B2M
B2M is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (158), Actionable biomarkers (1), Trial mentions (20), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention B2M. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 11 dated before 1990 and 8 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 1 of 8,738 | 0.01% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 43 of 11,460 | 0.38% |
| 2022 | 1 of 8,285 | 0.01% | 52 of 13,598 | 0.38% |
| 2021 | 0 of 8,692 | 0.00% | 64 of 15,045 | 0.43% |
| 2020 | 2 of 7,640 | 0.03% | 50 of 14,459 | 0.35% |
| 2019 | 0 of 7,300 | 0.00% | 52 of 12,159 | 0.43% |
| 2018 | 5 of 6,927 | 0.07% | 45 of 11,854 | 0.38% |
| 2017 | 1 of 6,558 | 0.02% | 45 of 11,595 | 0.39% |
Showing 10 of 37 years.
Assay-provider ledger (158)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Institute for Translational Research, University of North Texas Health Science Center (UNT Health Fort Worth) Omics Core | Not a company | Clinical validationAnalytical validation | 1 | July 01, 2026 |
| Meso Scale Discovery | Reagent supplier | Clinical validationAnalytical validation | 12 | July 01, 2026 +4 undated |
| National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) | Not a company | Clinical validationAnalytical validation | 1 | July 01, 2026 |
| Quanterix | Reagent supplier | Clinical validationAnalytical validation | 1 | July 01, 2026 |
| ROCHE DIAGNOSTICS | Context dependent | Clinical validationAnalytical validation | 8 | January 15, 2026 |
Showing 5 of 158 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| B2M oncogenic mutation | Pd1 Ab Inhibitors | responsive | cutaneous melanoma | Cancer Genome Interpreter |
Trial mentions (20)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04702958 | Trial biospecimen (AACT) |
| NCT02623920 | Trial eligibility (AACT) |
| NCT00477035 | Trial eligibility (AACT) |
| NCT04554498 | Trial eligibility (AACT) |
| NCT07454382 | Trial eligibility (AACT) |
Showing 5 of 20 trial mentions.
Target-disease associations (511)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 22q11.2 deletion syndrome | cardiovascular disease | Mouse knockout (IMPC) |
| 46,XX ovotesticular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| AIDS | genetic, familial or congenital disease | Literature (Europe PMC) |
| AIDS dementia | infectious disease | Literature (Europe PMC) |
| AL amyloidosis | cardiovascular disease | Literature (Europe PMC) |
Showing 5 of 511 associations.
Vendor sourcing (59)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.212A>G (p.H71R) alteration is located in exon 2 (coding exon 2) of the B2M gene. This alteration results from a A to G substitution at nucleotide posit... | View ClinVar record SCV003973191.2 |
| Assistance Publique Hôpitaux de Marseille | Trial collaborator | Mentioned in trial textTrial free-text mention | B2M | View trial NCT03610334 |
| Celgene (United States) | Trial sponsor | Mentioned in trial textTrial free-text mention | B2M | View trial NCT03310619 |
| Duke University | Trial collaborator | Biospecimen collected in a trialTrial biospecimen collection | No supporting text recorded; see the citation. | View trial NCT04702958 |
| Duke University | Trial collaborator | Mentioned in trial textTrial free-text mention | B2M | View trial NCT04702958 |
Showing 5 of 59 sourcing records.
Trial-cited literature (651)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Serum extracellular vesicle RNA profiles in long COVID: insights from exercise-induced gene modulation. | Scientific reports | 2026 | 0 |
| Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma. | Blood advances | 2025 | 6 |
| Effect of Dapagliflozin on Measured vs. Panel-Estimated Glomerular Filtration Rate. | Clinical pharmacology and therapeutics | 2025 | 4 |
| Lupus Nephritis Biomarkers: A Critical Review. | International journal of molecular sciences | 2024 | 34 |
| Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Proteomic Substudy. | Journal of the American Heart Association | 2024 | 14 |
Showing 5 of 651 papers.
Protein variant mentions (8)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.I117M | 1 | 2017 | PMID 28958678 |
| p.I117T | 1 | 2017 | PMID 28958678 |
| p.K150S | 1 | 2017 | PMID 28958678 |
| p.L12P | 1 | 2017 | PMID 28596308 |
| p.M1T | 2 | 2016 to 2020 | PMID 32304999, PMID 26619011 |
Showing 5 of 8 variants.
Human sample screening reference (2)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.L12P | TCGA-COAD | Epithelial Neoplasms, NOS; Adenomas and Adenocarcinomas; Cystic, Mucinous and Serous Neoplasms; Complex Epithelial Neoplasms; Rectosigmoid junction; Colon | 1 | 461 | 0.22% | 0.04% to 1.22% |
| p.L12P | TCGA-DLBC | Not Reported; Mature B-Cell Lymphomas; Colon; Stomach; Connective, subcutaneous and other soft tissues; Testis; Brain; Heart, mediastinum, and pleura; Other and unspecified major salivary glands; Breast; Small intestine; Bones, joints and articular cartilage of other and unspecified sites; Retroperitoneum and peritoneum; Thyroid gland; Lymph nodes; Hematopoietic and reticuloendothelial systems | 1 | 50 | 2.00% | 0.35% to 10.50% |
Literature-extracted relations (43)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| RITUXIMAB | Chemical | negative_correlate |
Lymphoid Interstitial Pneumonia in Common Variable Immune Deficiency - Case Report With Disease Monitoring in Various Therapeutic Options: Pleiotropic Effects of Rituximab Regimens. | 2018 |
| Lactulose | Chemical | negative_correlate |
Lactulose for reduction of nitrogen products in patients with chronic kidney disease. | 2014 |
| Theophylline | Chemical | negative_correlate |
Theophylline for renal function in term neonates with perinatal asphyxia: a randomized, placebo-controlled trial. | 2006 |
| Theophylline | Chemical | negative_correlate |
Prophylactic theophylline to prevent renal dysfunction in newborns exposed to perinatal asphyxia--a study in a developing country. | 2005 |
| Theophylline | Chemical | negative_correlate |
A randomized, double-blind, placebo-controlled trial of the effects of prophylactic theophylline on renal function in term neonates with perinatal asphyxia. | 2000 |
Showing 5 of 43 relation assertions.
Organizations publishing (552)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 30 | 1995 to 2023 |
| Harvard Medical School | Academic | 28 | 1996 to 2023 |
| Mayo Clinic | Hospital | 28 | 2000 to 2022 |
| Memorial Sloan Kettering Cancer Center | Hospital | 28 | 1991 to 2023 |
| Dana-Farber Cancer Institute | Other | 21 | 2010 to 2023 |
Showing 5 of 552 organizations.
Where B2M appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- respiratory or thoracic disease
- urinary system disease
479 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.